SCHEMBL5800381

SCHEMBL5800381

CC1(C)CC[C@]2(CO)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@]43C)[C@@H]2C1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 8/20 0.76
ALOX5 P09917 2/20 0.76
AKR1B10 O60218 3/20 0.70
AKR1B1 P15121 3/20 0.70
F3 P13726 2/20 0.59
CYP3A4 P08684 2/20 0.59
USP2 O75604 1/20 0.59
LMNA P02545 1/20 0.59
USP7 Q93009 1/20 0.59
SLCO1B3 Q9NPD5 1/20 0.59
SLCO1B1 Q9Y6L6 1/20 0.59
GABRP O00591 1/20 0.59
GABRD O14764 1/20 0.59
GABRA1 P14867 1/20 0.59
GABRB1 P18505 1/20 0.59
GABRG2 P18507 1/20 0.59
GABRB3 P28472 1/20 0.59
GABRA5 P31644 1/20 0.59
GABRA3 P34903 1/20 0.59
GABRA2 P47869 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5800384 1.00 PTPN1 (0.76) PTPN1ALOX5AKR1B10AKR1B1F3
SCHEMBL5796496 0.91 ALOX5 (0.78) PTPN1ALOX5AKR1B10AKR1B1F3
SCHEMBL5796497 0.91 ALOX5 (0.78) PTPN1ALOX5AKR1B10AKR1B1F3
SCHEMBL5013122 0.91 PTPN1 (0.78) PTPN1ALOX5AKR1B10AKR1B1PYGM
SCHEMBL1051068 0.91 PTPN1 (0.78) PTPN1ALOX5AKR1B10AKR1B1PYGM
SCHEMBL4736386 0.91 PTPN1 (0.77) PTPN1ALOX5AKR1B10AKR1B1F3
SCHEMBL4736389 0.88 PTPN1 (0.73) PTPN1ALOX5AKR1B10AKR1B1F3
SCHEMBL16704696 0.88 PTPN1 (0.83) PTPN1ALOX5AKR1B10AKR1B1F3
SCHEMBL17332299 0.88 PTPN1 (0.83) PTPN1ALOX5AKR1B10AKR1B1F3
Arjunolic Acid SCHEMBL24135094 0.86 PTPN1 (1.00) PTPN1ALOX5AKR1B10AKR1B1F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060235078-A1 Insulin secretion potentiator USE-TECHNO CORPORATION 2006-10-19 US disclosed
EP-1674089-A1 ACCELERATOR FOR INITIAL INSULIN SECRETION Use-Techno Corporation (JP) 2006-06-28 EP disclosed
WO-2006054370-A1 GLUCONEOGENESIS INHIBITING AGENT USE-TECHNO CORPORATION (JP) 2006-05-26 WO disclosed
US-20050143464-A1 With low side effects, which rapidly stimulate early insulin secretion and suppress blood glucose increase only at mealtimes; antidiabetic agent; triterpene acids or alcohols with picene ring; corosolic acids; oleanene acids; ursenoic acids; banaba plant extracts USE-TECHNO CORPORATION 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143464-A1 With low side effects, which rapidly stimulate early insulin secretion and suppress blood glucose increase only at mealtimes; antidiabetic agent; triterpene acids or alcohols with picene ring; corosolic acids; oleanene acids; ursenoic acids; banaba plant extracts GPR119, IRS1, AMY1A PTPN1 1873/4885ALOX5 511/4885AKR1B10 1998/4885
US-20060235078-A1 Insulin secretion potentiator IAPP, GPR119, IRS1 PTPN1 1481/4885ALOX5 3951/4885AKR1B10 1544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.